Type 2 diabetes

Davies, M. J., Alibegovic, A. C., Kelkar, P., Braae, U. C., & Jensen, A. B. (2023). Glycaemic control and weight outcomes after adding or switching to biphasic insulin aspart 30/70 in people with type 2 diabetes mellitus previously treated with basal-bolus insulin in UK clinical practice. Diabetes Obes Metab. http://doi.org/10.1111/dom.15278
Abrahami, D., D'Andrea, E., Yin, H., Kim, S. C., Paik, J. M., Wexler, D., et al. (2023). Contemporary trends in the utilization of second-line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom. Diabetes Obes Metab. http://doi.org/10.1111/dom.15196
van Hulten, V., Driessen, J. H. M., Starup-Linde, J. K., Al-Mashhadi, Z. K., Viggers, R., Klungel, O. H., et al. (2023). The associations of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as add-on to metformin with fracture risk in patients with type 2 diabetes mellitus. Diabetes Obes Metab. http://doi.org/10.1111/dom.15220
Zheng, B., Su, B., Ahmadi-Abhari, S., Kapogiannis, D., Tzoulaki, I., Riboli, E., & Middleton, L. (2023). Dementia risk in patients with type 2 diabetes: Comparing metformin with no pharmacological treatment. Alzheimers Dement. http://doi.org/10.1002/alz.13349
Raslan, A. S., Quint, J. K., & Cook, S. (2023). All-Cause, Cardiovascular and Respiratory Mortality in People with Type 2 Diabetes and Chronic Obstructive Pulmonary Disease (COPD) in England: A Cohort Study Using the Clinical Practice Research Datalink (CPRD). Int J Chron Obstruct Pulmon Dis, 18, 1207-1218. http://doi.org/10.2147/copd.s407085
Davies, M. J., Alibegovic, A. C., Jensen, A. B., Munikrishnappa, R., Nordsborg, R. B., & Braae, U. C. (2023). Real-world study of ethnic differences in glycaemic control and clinical characteristics among insulin-naïve people with type 2 diabetes initiating biphasic insulin aspart 30/70: A retrospective, observational cohort study in England. Diabetes Obes Metab. http://doi.org/10.1111/dom.15165
Venkatasubramaniam, A., Mateen, B. A., Shields, B. M., Hattersley, A. T., Jones, A. G., Vollmer, S. J., & Dennis, J. M. (2023). Comparison of causal forest and regression-based approaches to evaluate treatment effect heterogeneity: an application for type 2 diabetes precision medicine. Bmc Med Inform Decis Mak, 23, 110. http://doi.org/10.1186/s12911-023-02207-2
Larose, S., Filliter, C., Platt, R. W., H. Y. Yu, O., & Filion, K. B. (2023). Long-acting insulin analogues and the risk of diabetic retinopathy among patients with type 2 diabetes: A population-based cohort study. Diabetes Obes Metab. http://doi.org/10.1111/dom.15106
Jeffery, A., Bhanu, C., Walters, K., Wong, I. C., Osborn, D., & Hayes, J. F. (2023). Polypharmacy and antidepressant acceptability in comorbid depression and type 2 diabetes: a cohort study using UK primary care data. Br J Gen Pract, 73, e392-e398. http://doi.org/10.3399/bjgp.2022.0295
Lai, H. T. M., Chang, K., Sharabiani, M. T. A., Valabhji, J., Gregg, E. W., Middleton, L., et al. (2023). Twenty-year trajectories of cardio-metabolic factors among people with type 2 diabetes by dementia status in England: a retrospective cohort study. Eur J Epidemiol. http://doi.org/10.1007/s10654-023-00977-7